

Exploring the Mechanism of Action of Bromocriptine Derivatives in Parkinson's Disease

Niharika Modi¹, Muhammed Ameen MP², Bikramaditya Mukherjee³, Ritu⁴, Amandeep Kaur⁵, Gunosindhu Chakraborty⁶, Rajeev Ranjan⁷, Deepak Nanda^{8*}

¹Research Scholar, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreshwara Nagara, Mysuru, Karnataka

²Assistant Professor, Department of Pharmacology, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University) Mangaluru

³Assistant Professor, Department of Biochemistry, Manipal Tata Medical College, Jamshedpur, Manipal Academy of Higher Education, Manipal

⁴Assistant professor, Ch. Devi Lal College of Pharmacy, Jagadhari, Haryana

⁵Assistant Professor, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar

⁶Principal and Professor, Parul Institute of Pharmacy and Research, Parul University, Limda, Waghodia, Vadodara, Gujarat

⁷Assistant Professor, University Department of Chemistry, DSPM University, Ranchi

^{8*}Professor and Dean, School of Pharmaceutical Sciences, Jigyasa University, Dehradun, Uttarakhand

Corresponding Author: ^{8*}Prof. (Dr.) Deepak Nanda

^{8*}Professor and Dean, School of Pharmaceutical Sciences, Jigyasa University, Dehradun, Uttarakhand

Email Id: ^{8*}dean.pharmacy@hzu.edu.in

Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor and non-motor symptoms. Dopamine replacement therapies, such as levodopa, have been the cornerstone of PD treatment; however, long-term use is associated with motor complications. Dopamine agonists, including bromocriptine and its derivatives, offer an alternative by directly stimulating dopamine receptors, providing symptomatic relief and potential neuroprotective effects. This review aims to explore the mechanisms of action of bromocriptine derivatives in the treatment of PD, focusing on their receptor binding profiles, modulation of dopaminergic pathways, and neuroprotective properties. Bromocriptine, a semi-synthetic ergot alkaloid, primarily targets dopamine D2 receptors, with additional activity at D3 and D4 receptors. Its molecular structure allows high affinity and selectivity for these receptors, mimicking the action of endogenous dopamine. Bromocriptine's pharmacodynamics include potent agonistic effects on postsynaptic dopamine receptors, which help alleviate PD symptoms by enhancing dopaminergic signaling in the brain. Furthermore, bromocriptine exhibits a favorable pharmacokinetic profile, with good oral bioavailability and a relatively long half-life, ensuring sustained therapeutic effects. In the context of dopaminergic pathways, bromocriptine derivatives play a significant role in modulating the nigrostriatal pathway,

which is crucial for motor control. By stimulating D2 receptors, bromocriptine enhances dopamine release and inhibits its reuptake, thereby increasing dopaminergic transmission. This modulation helps restore the balance of dopamine in the brain, improving motor function and reducing PD symptoms such as tremors, rigidity, and bradykinesia. Additionally, bromocriptine has been shown to influence other brain regions involved in cognitive and emotional functions, potentially offering benefits for non-motor symptoms of PD, such as depression and cognitive decline. Moreover, studies suggest that bromocriptine can promote neurogenesis and enhance mitochondrial function, contributing to overall neuronal health and resilience. Future studies should focus on developing new formulations, improving delivery methods, and exploring combination therapies to maximize the therapeutic potential of bromocriptine derivatives in PD.

Keywords: Parkinson's disease, bromocriptine, dopamine agonists, dopaminergic pathways, neuroprotection, D2 receptors, pharmacodynamics

1. Introduction

Parkinson's Disease (PD) is a chronic, progressive neurodegenerative disorder primarily affecting the motor system. It was first described by James Parkinson in 1817 and has since been recognized as a major neurological condition affecting millions worldwide[1]. The hallmark symptoms of PD include tremor at rest, bradykinesia (slowness of movement), rigidity (stiffness of the limbs and trunk), and postural instability (impaired balance and coordination)[2]. These motor symptoms are primarily due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta, a region of the brain involved in the regulation of movement[3]. The loss of these neurons leads to a significant decrease in dopamine levels, a critical neurotransmitter that facilitates smooth and coordinated muscle movements[4]. While the exact cause of neuron degeneration in PD remains unclear, it is believed to be due to a combination of genetic and environmental factors. Mutations in specific genes, such as SNCA, PARK2, and LRRK2, have been implicated in familial forms of PD[5]. Environmental factors, such as exposure to pesticides and heavy metals, have also been associated with an increased risk of developing PD[6]. Dopamine agonists play a crucial role in the management of Parkinson's Disease. They are compounds that mimic the action of dopamine by directly stimulating dopamine receptors in the brain[7]. Unlike levodopa, the precursor to dopamine, which requires conversion to dopamine in the brain, dopamine agonists do not depend on the presence of functional dopaminergic neurons and can exert their effects directly on dopamine receptors[8].

The primary therapeutic goal in PD is to restore dopaminergic function and alleviate motor symptoms. Dopamine agonists are often used in the early stages of PD, either as monotherapy or in combination with levodopa[9]. They help to reduce the severity of motor symptoms and can delay the need for levodopa therapy, which is associated with long-term complications such as motor fluctuations and dyskinesias (involuntary movements). Moreover, dopamine agonists have a longer half-life than levodopa, providing more stable dopaminergic stimulation and reducing the risk of motor complications[10,4]. They also have beneficial effects on non-motor symptoms of PD, such as depression, sleep disturbances, and restless legs syndrome[11]. However, dopamine agonists are associated with side effects such as nausea, orthostatic hypotension (drop in blood pressure upon standing), and impulse control disorders (e.g., compulsive gambling, eating, or shopping)[12]. The objective of this review

is to provide a comprehensive overview of the mechanisms of action of bromocriptine derivatives in the treatment of Parkinson's Disease. Bromocriptine is a well-known dopamine agonist that has been used in the treatment of PD for several decades. It is derived from ergot alkaloids and exerts its effects primarily by stimulating dopamine D2 receptors. Over the years, various derivatives of bromocriptine have been developed with the aim of enhancing its therapeutic efficacy and reducing side effects.

2. Parkinson's Disease: Pathophysiology and Treatment Landscape

Dopaminergic Neuron Degeneration

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, a region of the midbrain crucial for movement control. This neuronal degeneration leads to a significant reduction in dopamine, a neurotransmitter essential for the smooth execution of voluntary movements [13]. The exact cause of dopaminergic neuron death in PD is multifactorial, involving genetic mutations, environmental exposures, and cellular dysfunctions. One of the hallmark pathological features of PD is the presence of Lewy bodies, which are abnormal aggregates of the protein alpha-synuclein found within neurons [14,3]. The misfolding and aggregation of alpha-synuclein disrupt various cellular processes, including mitochondrial function and protein degradation pathways, ultimately leading to neuronal death. Additionally, mitochondrial dysfunction plays a significant role in PD pathogenesis. Mitochondria are the energy powerhouses of cells, and their impairment leads to increased oxidative stress—a condition where reactive oxygen species (ROS) damage cellular components, contributing to cell death. Genetic factors are also implicated in PD [15]. Mutations in genes such as SNCA (encoding alpha-synuclein), LRRK2 (leucine-rich repeat kinase 2), PARK2 (parkin), and PINK1 (PTEN-induced putative kinase 1) disrupt normal cellular functions, including protein degradation, mitochondrial maintenance, and synaptic transmission, thereby contributing to neuronal degeneration [16,2]. In addition to genetic and mitochondrial factors, inflammation and immune system dysregulation are increasingly recognized as critical contributors to PD. Activated microglia, the resident immune cells of the brain, release pro-inflammatory cytokines in response to neuronal damage, leading to chronic neuroinflammation that exacerbates neuronal injury [17].

Role of Dopamine in Motor Control

Dopamine is a key neurotransmitter involved in several brain functions, including motor control, motivation, and reward [18]. In the context of motor control, dopamine's role is primarily mediated through the nigrostriatal pathway, where dopaminergic neurons project from the substantia nigra to the striatum, a crucial part of the basal ganglia [19]. The basal ganglia, a group of subcortical nuclei, are essential for coordinating movement by receiving input from the cerebral cortex and sending output to the motor cortex via the thalamus [20]. Dopamine modulates the activity of the direct and indirect pathways within the basal ganglia. The direct pathway facilitates movement by promoting thalamic activation, while the indirect pathway inhibits movement by suppressing thalamic activity [21,19]. Dopamine enhances the direct pathway through excitatory D1 receptors and suppresses the indirect pathway through inhibitory D2 receptors. In PD, the loss of dopaminergic neurons leads to decreased dopamine levels, disrupting the balance between these pathways [16]. This imbalance results in reduced facilitation of movement (due to decreased stimulation of D1 receptors) and

excessive inhibition of movement (due to reduced inhibition of D2 receptors), manifesting as the cardinal motor symptoms of PD: bradykinesia, rigidity, and tremor[3,12].

Current Treatment Approaches

Dopamine replacement therapy is the cornerstone of PD treatment, aiming to replenish the diminished levels of dopamine in the brain. The most effective and widely used dopamine replacement therapy is levodopa (L-DOPA), the precursor to dopamine[22]. Levodopa is converted to dopamine in the brain by the enzyme aromatic L-amino acid decarboxylase (AADC)[17]. To increase the availability of levodopa in the central nervous system and reduce peripheral side effects such as nausea and vomiting, it is administered with carbidopa or benserazide, peripheral AADC inhibitors that prevent levodopa's conversion to dopamine outside the brain[23]. Levodopa significantly improves motor symptoms in PD patients, including bradykinesia, rigidity, and tremor. However, long-term use of levodopa is associated with complications such as motor fluctuations (wearing-off phenomenon) and dyskinesias (involuntary movements). Motor fluctuations are characterized by a waning effect of each levodopa dose, leading to periods of decreased mobility (off periods) between doses[24]. Dyskinesias typically occur at the peak of levodopa's effect and are thought to result from the pulsatile stimulation of dopamine receptors due to intermittent dosing[19]. To address these issues, strategies have been developed to provide more continuous dopaminergic stimulation, such as extended-release formulations of levodopa (e.g., controlled-release carbidopa-levodopa) and continuous intraduodenal infusion of levodopa-carbidopa gel. These approaches aim to reduce motor fluctuations and improve overall symptom control [25,7].

Role of Dopamine Agonists and Their Advantages

Dopamine agonists are another key component of PD treatment. Unlike levodopa, dopamine agonists do not require conversion to dopamine and directly stimulate dopamine receptors in the brain[26]. There are two main classes of dopamine agonists: ergoline derivatives (e.g., bromocriptine, pergolide) and non-ergoline derivatives (e.g., pramipexole, ropinirole, rotigotine, apomorphine). Dopamine agonists offer several advantages over levodopa[27]. They have a longer half-life, providing more stable dopaminergic stimulation and reducing the risk of motor complications[28]. Dopamine agonists can be used as monotherapy in the early stages of PD to delay the initiation of levodopa therapy and the onset of levodopa-induced motor complications. They are also used in combination with levodopa in advanced PD to reduce motor fluctuations and extend the duration of levodopa's effect[29]. Pramipexole and ropinirole are commonly used non-ergoline dopamine agonists. Pramipexole has a high affinity for D3 receptors, which are thought to play a role in mood and motivation, potentially providing additional benefits for non-motor symptoms such as depression. Ropinirole has a high affinity for D2 receptors and is effective in reducing motor symptoms and motor fluctuations. Rotigotine is a dopamine agonist available as a transdermal patch, providing continuous dopaminergic stimulation over 24 hours[12,5]. This mode of delivery helps maintain stable plasma drug levels and reduces the risk of motor complications. Apomorphine is a potent, fast-acting dopamine agonist used for the acute management of off episodes in advanced PD[30]. It can be administered subcutaneously and provides rapid relief of motor symptoms. While dopamine agonists offer several benefits, they are associated with side effects such as nausea, orthostatic hypotension, somnolence, and impulse control disorders (e.g., compulsive gambling, eating, shopping, and hypersexuality).

Therefore, the choice of therapy must be individualized based on the patient's symptoms, disease stage, and tolerance to side effects[31,4].

Other Treatment Approaches

In addition to dopamine replacement therapy and dopamine agonists, several other pharmacological and non-pharmacological treatments are used to manage PD[32]. Monoamine oxidase-B (MAO-B) inhibitors, such as selegiline and rasagiline, inhibit the breakdown of dopamine in the brain, thereby increasing its availability and providing symptomatic relief[18]. Catechol-O-methyltransferase (COMT) inhibitors, such as entacapone and tolcapone, prolong the effect of levodopa by inhibiting its peripheral metabolism[33]. Amantadine is an NMDA receptor antagonist with mild antiparkinsonian effects and is particularly useful for managing levodopa-induced dyskinesias[2]. Anticholinergic drugs, such as trihexyphenidyl and benztropine, can be used to treat tremor, especially in younger patients, but are generally avoided in older patients due to their cognitive side effects. Deep brain stimulation (DBS) is a surgical treatment option for advanced PD patients who experience significant motor fluctuations and dyskinesias despite optimal medical therapy[19]. DBS involves the implantation of electrodes in specific brain regions, such as the subthalamic nucleus or globus pallidus internus, to modulate abnormal neuronal activity and improve motor symptoms. Non-pharmacological treatments, including physical therapy, occupational therapy, speech therapy, and exercise, play an essential role in managing PD and improving the quality of life[22]. Regular exercise has been shown to have neuroprotective effects and can help maintain mobility, balance, and overall physical function[34].

3. Bromocriptine and Its Derivatives: Chemical Structure and Pharmacology

Chemical Structure of Bromocriptine

Bromocriptine is a semisynthetic derivative of ergot, a group of compounds derived from the ergot fungus *Claviceps purpurea*. Its molecular structure is complex, featuring a brominated ergoline skeleton, which is a bicyclic structure combining an indole ring with a piperidine ring[2]. The full chemical name of bromocriptine is 2-bromo- α -ergocryptine, and its molecular formula is $C_{32}H_{40}BrN_5O_5$. The structure of bromocriptine is characterized by the presence of a bromine atom attached to the 2-position of the ergoline ring system. This bromination is a significant modification that enhances its pharmacological activity[19,7]. The molecule also includes multiple chiral centers, which give it specific stereochemistry essential for its biological activity. The ergoline backbone of bromocriptine allows it to interact with dopamine receptors, particularly the D2 subtype, which plays a crucial role in its mechanism of action[8].




Figure 1: Structure of Bromocriptine

Comparison with Other Dopamine Agonists

Compared to other dopamine agonists, bromocriptine has unique structural features[4]. For instance, non-ergoline dopamine agonists such as pramipexole and ropinirole lack the ergoline backbone and instead possess simpler, smaller molecular structures[3]. Pramipexole, for example, is a thiazole derivative, while ropinirole is an indolone derivative[19]. These structural differences contribute to variations in receptor binding affinity, pharmacokinetics, and side effect profiles[12]. Ergoline derivatives like bromocriptine and pergolide share a common structural motif but differ in their substituents and specific configurations[23]. Pergolide, for instance, contains additional alkyl groups compared to bromocriptine, affecting its receptor binding and pharmacological effects. Non-ergoline agonists tend to have fewer side effects related to ergot toxicity, such as fibrosis and vasospasm, which are sometimes associated with ergoline compounds like bromocriptine[35]. The bromination in bromocriptine distinguishes it from other ergoline derivatives, contributing to its potency and specificity for dopamine receptors. This unique structural attribute makes bromocriptine particularly effective in mimicking the action of dopamine in the brain, thereby compensating for the dopamine deficit seen in Parkinson's Disease (PD)[6].

Pharmacological Profile

Pharmacodynamics

The pharmacodynamics of bromocriptine revolve around its role as a dopamine D2 receptor agonist. By binding to these receptors, bromocriptine mimics the action of dopamine, thereby exerting its therapeutic effects in PD[36]. Dopamine D2 receptors are primarily involved in the regulation of motor function, and their activation helps alleviate the motor symptoms associated with PD, such as bradykinesia, rigidity, and tremor[37,17]. In addition to its dopaminergic activity, bromocriptine has partial agonist activity at D1 receptors and antagonist activity at serotonin (5-HT) receptors, which may contribute to its overall pharmacological profile. This broad receptor activity can help reduce prolactin levels, explaining bromocriptine's use in conditions like hyperprolactinemia[19]. The interaction with multiple receptor types also underscores the potential for a diverse range of therapeutic effects and side effects. Bromocriptine's ability to stimulate dopamine receptors without being converted to dopamine allows it to provide more stable dopaminergic stimulation compared to levodopa[2,4]. This property helps reduce the incidence of motor fluctuations and dyskinesias, common complications with long-term levodopa use[38].

Pharmacokinetics

The pharmacokinetics of bromocriptine involve its absorption, distribution, metabolism, and excretion. Bromocriptine is orally administered and has a variable absorption rate, with peak plasma concentrations typically occurring 1-2 hours post-administration. However, its bioavailability is relatively low, around 6%, due to extensive first-pass metabolism in the liver[12]. After absorption, bromocriptine is widely distributed throughout the body, including crossing the blood-brain barrier to reach central nervous system targets[22]. It is highly bound to plasma proteins, which facilitates its distribution but also affects its half-life and duration of action. Metabolism of bromocriptine occurs primarily in the liver via cytochrome P450 enzymes, particularly CYP3A4. This metabolism produces several metabolites, some of which retain pharmacological activity, potentially contributing to the drug's overall effect profile[18]. The extensive first-pass metabolism also means that variations in liver enzyme activity can significantly affect the drug's efficacy and safety. The elimination half-life of bromocriptine is approximately 12-14 hours, allowing for once or twice daily dosing in most therapeutic regimens[39]. The metabolites of bromocriptine are primarily excreted via the bile and feces, with minimal renal excretion. This elimination pattern means that patients with liver impairment may require dose adjustments, whereas those with renal impairment generally do not[4,5].

4. Mechanism of Action of Bromocriptine Derivatives

Specific Receptors Targeted (D2 Receptors)

Bromocriptine and its derivatives primarily target dopamine D2 receptors, which are crucial for their therapeutic effects in Parkinson's Disease (PD). Dopamine receptors are classified into D1-like and D2-like families, with D2 receptors belonging to the latter group[3]. The D2 receptors are predominantly located in the striatum, a critical component of the basal ganglia involved in regulating motor control[18]. Bromocriptine's affinity for D2 receptors allows it to mimic the action of endogenous dopamine, which is deficient in PD due to the degeneration of dopaminergic neurons in the substantia nigra. In addition to D2 receptors, bromocriptine has some activity at D3 and D4 receptors, which also belong to the D2-like family[22]. These receptors are implicated in mood regulation and reward pathways, suggesting that bromocriptine might also influence non-motor symptoms of PD, such as depression and apathy[2]. The broader receptor profile of bromocriptine derivatives can contribute to a more comprehensive therapeutic effect beyond just motor symptom relief[40].




Figure 2: Bromocriptine and its derivatives primarily target dopamine D2 receptor.

Affinity and Selectivity

Bromocriptine exhibits high affinity for D2 receptors, making it effective in low doses and reducing the likelihood of off-target effects. This high affinity ensures that bromocriptine can efficiently activate D2 receptors, compensating for the decreased dopaminergic activity in PD[41]. The selectivity of bromocriptine for D2 over D1 receptors is beneficial, as excessive stimulation of D1 receptors can lead to undesirable side effects such as dyskinesias[42]. The high affinity and selectivity of bromocriptine derivatives for D2 receptors also contribute to their efficacy in reducing prolactin levels by inhibiting prolactin secretion from the anterior pituitary gland, a property that is particularly useful in treating hyperprolactinemia[1,3]. This dual action on both central and peripheral dopamine receptors underscores the versatility of bromocriptine derivatives in treating various dopaminergic disorders[43].

Modulation of Dopaminergic Pathways

Effects on Nigrostriatal Pathways

The primary therapeutic effect of bromocriptine in PD is its modulation of the nigrostriatal pathway, which is critically involved in motor control[4]. The nigrostriatal pathway comprises dopaminergic neurons projecting from the substantia nigra to the striatum[29]. In PD, the degeneration of these neurons leads to a significant reduction in dopamine levels within the striatum, disrupting the balance between the direct and indirect pathways of the basal ganglia. By stimulating D2 receptors in the striatum, bromocriptine helps restore the balance between these pathways[19]. Activation of D2 receptors inhibits the indirect pathway, reducing the excessive inhibitory output from the basal ganglia that characterizes PD[1]. This action alleviates motor symptoms such as bradykinesia, rigidity, and tremor, thereby improving motor function and quality of life for PD patients[46].

Impact on Dopamine Synthesis and Release

In addition to directly stimulating dopamine receptors, bromocriptine may influence the synthesis and release of endogenous dopamine. Bromocriptine's action on presynaptic D2 autoreceptors, which regulate dopamine synthesis and release, can modulate dopaminergic activity[19]. Activation of these autoreceptors typically inhibits dopamine synthesis and release, providing a feedback mechanism to maintain dopamine levels within an optimal range[47]. Bromocriptine's effect on dopamine synthesis and release is complex and can vary depending on the physiological state of the dopaminergic system[2]. In the context of PD, where dopamine levels are depleted, bromocriptine's primary therapeutic action is its agonism at postsynaptic D2 receptors, enhancing dopaminergic transmission despite the reduced endogenous dopamine production[48].

Neuroprotective Effects

Antioxidant Properties

Beyond its dopaminergic actions, bromocriptine exhibits neuroprotective effects that can contribute to its overall therapeutic benefit in PD. One such effect is its antioxidant properties. Oxidative stress, characterized by the excessive production of reactive oxygen species (ROS), is a significant factor in the pathogenesis of PD[17]. ROS can damage cellular components, leading to neuronal death. Bromocriptine's antioxidant activity involves scavenging free radicals and reducing oxidative damage within the brain[23]. By mitigating oxidative stress, bromocriptine helps protect dopaminergic neurons from further

degeneration. This neuroprotective action can slow the progression of PD and preserve motor function for a longer duration[1,8].

Inhibition of Neuroinflammation

Neuroinflammation is another critical factor in the progression of PD, with activated microglia releasing pro-inflammatory cytokines that exacerbate neuronal damage[21,4]. Bromocriptine has been shown to exert anti-inflammatory effects by modulating the activity of microglia and reducing the production of inflammatory mediators[49]. This anti-inflammatory action helps create a more favorable environment for neuronal survival. By inhibiting neuroinflammation, bromocriptine not only protects existing dopaminergic neurons but also potentially enhances the efficacy of other therapeutic interventions. The combined antioxidant and anti-inflammatory properties of bromocriptine provide a multifaceted neuroprotective effect that extends beyond its role as a dopamine receptor agonist[50].

TABLE 1. summarizing the adverse effects of dopamine agonists

Adverse Effect	Description	Common Dopamine Agonists Involved	References
Nausea and Vomiting	Gastrointestinal discomfort, often leading to nausea and vomiting	Bromocriptine, Pramipexole, Ropinirole	[3]
Orthostatic Hypotension	Sudden drop in blood pressure upon standing, causing dizziness and lightheadedness	Bromocriptine, Pramipexole, Ropinirole	[21]
Somnolence	Excessive daytime sleepiness and sudden sleep episodes	Pramipexole, Ropinirole, Apomorphine	[44]
Hallucinations	Visual or auditory hallucinations, more common in elderly patients	Pramipexole, Ropinirole, Bromocriptine	[22]
Impulse Control Disorders	Compulsive behaviors such as gambling, shopping, eating, or hypersexuality	Pramipexole, Ropinirole, Bromocriptine	[14]
Peripheral Edema	Swelling of the legs and feet due to fluid retention	Pramipexole, Ropinirole	[29]
Dyskinesia	Involuntary, erratic, writhing movements of the face, arms, legs, or trunk	Levodopa (when used with dopamine agonists)	[5]
Fibrotic Complications	Development of fibrotic tissues in organs such as the heart (cardiac valvulopathy) and lungs	Pergolide (withdrawn), Cabergoline	[39]
Sleep Disturbances	Insomnia or disrupted sleep patterns	Ropinirole, Pramipexole	[27]
Psychosis	Severe mental disorders characterized by distorted thinking and a loss of contact with reality	Bromocriptine, Pramipexole, Ropinirole	[7]
Headache	Persistent or severe headaches	Bromocriptine, Ropinirole	[18]

Fatigue	General feeling of tiredness or lack of energy	Pramipexole, Ropinirole	[6]
Constipation	Difficulty in passing stools	Pramipexole, Ropinirole	[11]
Nasal Congestion	Blocked or runny nose	Bromocriptine	[20]
Confusion	Difficulty in thinking clearly or understanding surroundings	Pramipexole, Ropinirole	[11]

5. Comparative Analysis with Other Dopamine Agonists

Comparison with Other Common Dopamine Agonists

Bromocriptine, pramipexole, and ropinirole are prominent dopamine agonists used in the treatment of Parkinson's Disease (PD). These medications share the common goal of stimulating dopamine receptors to compensate for the dopamine deficiency characteristic of PD, yet they have distinct pharmacological profiles and clinical uses[13,4].

Pramipexole

Pramipexole is a non-ergoline dopamine agonist that selectively binds to dopamine D2, D3, and D4 receptors, with a particular affinity for D3 receptors. This selectivity is thought to contribute to its efficacy in both motor and non-motor symptoms of PD, including depressive symptoms[21,7]. Pramipexole is available in immediate-release and extended-release formulations, allowing for flexible dosing and sustained symptom control. Studies have shown that pramipexole is highly effective in reducing motor symptoms and has a favorable impact on quality of life[52].

Ropinirole

Ropinirole is another non-ergoline dopamine agonist that primarily targets D2 and D3 receptors. It is used both as monotherapy in early PD and as an adjunct to levodopa in advanced stages. Ropinirole is available in immediate-release and extended-release forms, providing options for tailored treatment regimens[18]. Clinical trials demonstrate that ropinirole effectively reduces motor symptoms and can help manage motor fluctuations when used in combination with levodopa[53].

Other Dopamine Agonists

Other dopamine agonists include rotigotine, available as a transdermal patch, and apomorphine, administered via injection or infusion. Rotigotine provides continuous dopaminergic stimulation through transdermal delivery, which can be particularly beneficial for patients with nocturnal symptoms or those who have difficulty swallowing pills[19,4]. Apomorphine is often reserved for rescue therapy due to its rapid onset of action and is used to manage sudden "off" episodes[54].

Advantages and Disadvantages

When comparing bromocriptine with other dopamine agonists, several factors must be considered: efficacy in symptom control, safety profile, and tolerability.

Efficacy

All dopamine agonists, including bromocriptine, pramipexole, and ropinirole, are effective in managing motor symptoms of PD. However, their efficacy in non-motor symptoms varies[19,8]. Pramipexole, with its higher affinity for D3 receptors, is particularly noted for its antidepressant effects, which can be a significant advantage for patients with PD-associated depression. Ropinirole also shows benefits in both motor and non-motor symptoms but is generally less potent in mood improvement compared to pramipexole[55].

Safety

Bromocriptine, as an ergoline derivative, carries a risk of fibrosis, including pulmonary, retroperitoneal, and cardiac valvular fibrosis. This risk necessitates regular monitoring, such as echocardiograms, in patients on long-term bromocriptine therapy[29]. In contrast, non-ergoline dopamine agonists like pramipexole and ropinirole have a lower risk of these fibrotic complications, making them safer for long-term use. Both bromocriptine and non-ergoline agonists can cause side effects like nausea, vomiting, orthostatic hypotension, and hallucinations[27,9]. However, the incidence and severity of these side effects can vary. Pramipexole and ropinirole are often associated with a higher risk of impulse control disorders (ICDs), such as compulsive gambling and hypersexuality. Bromocriptine also poses a risk for ICDs but typically to a lesser extent[57].

Tolerability

Tolerability profiles differ among dopamine agonists. Bromocriptine is often associated with gastrointestinal side effects, which can be mitigated by gradual dose titration and administration with food[5]. Pramipexole and ropinirole are generally better tolerated in this regard but may still cause significant nausea and orthostatic hypotension, particularly at the start of therapy[22]. Non-ergoline agonists tend to be better tolerated regarding long-term use and are preferred for patients at higher risk of fibrotic complications. However, they require careful monitoring for psychiatric side effects and impulse control disorders[58].

Advantages and Disadvantages

Bromocriptine has the advantage of a well-established history and efficacy in both monotherapy and as an adjunct to levodopa. It is particularly useful in reducing levodopa-induced dyskinesias and motor fluctuations[2,45]. However, the risk of fibrotic complications and the necessity for regular monitoring are significant disadvantages. Pramipexole offers superior efficacy in non-motor symptoms, especially depression, and has a lower risk of fibrotic side effects. Its extended-release formulation provides convenient dosing options, but the higher risk of ICDs and psychiatric side effects requires vigilance[18,9]. Ropinirole shares many advantages with pramipexole, including flexible dosing and efficacy in motor and non-motor symptoms. It also carries a lower risk of fibrotic complications but is similarly associated with a risk of ICDs and psychiatric side effects[25]. The choice of dopamine agonist for PD treatment should be individualized based on the patient's symptom profile, comorbidities, and risk factors. Bromocriptine remains a valuable option, particularly in patients with motor complications and those who tolerate it well, while non-ergoline agonists like pramipexole and ropinirole offer significant benefits, especially for those at risk of fibrotic side effects[59].

6. Emerging Research and Future Directions

Recent research in bromocriptine derivatives focuses on developing new formulations and delivery methods to enhance their efficacy and tolerability in Parkinson's Disease (PD) treatment. Traditional oral administration of bromocriptine can lead to gastrointestinal side effects and variable absorption rates, prompting the exploration of alternative delivery systems[19]. One promising advancement is the development of extended-release (ER) formulations. These ER formulations provide a more consistent plasma concentration of the drug, reducing the frequency of dosing and potentially minimizing side effects associated with peak drug levels[60]. The steady release of bromocriptine can improve patient compliance and overall treatment outcomes by providing more stable symptom control throughout the day. Transdermal delivery systems, such as patches, are another innovative approach[16]. These systems offer several advantages over oral formulations, including bypassing the gastrointestinal tract, reducing first-pass metabolism, and providing a steady release of the drug. Transdermal patches can be particularly beneficial for patients who experience nausea and vomiting with oral bromocriptine or have difficulty swallowing pills[3]. Additionally, this method can improve drug adherence and provide a more predictable pharmacokinetic profile. Inhalable formulations of bromocriptine are also being investigated. These formulations aim to deliver the drug directly to the bloodstream via the lungs, offering rapid onset of action and improved bioavailability. This method could be advantageous for managing acute "off" episodes in PD, where quick symptom relief is needed[61].

Combination Therapies

Combination therapies involving bromocriptine and other medications are being explored to enhance the overall efficacy and reduce the side effects of PD treatment. One approach is combining bromocriptine with other dopamine agonists or levodopa to optimize dopaminergic stimulation while minimizing the risk of motor complications[2,7]. For example, a combination therapy can help manage motor fluctuations by providing a more balanced dopaminergic effect and reducing the total dose of each medication required[62]. Researchers are also investigating the use of bromocriptine in combination with non-dopaminergic treatments. These include medications targeting other neurotransmitter systems, such as glutamate antagonists and adenosine A2A receptor antagonists[33]. These combinations aim to provide a more comprehensive treatment approach by addressing multiple aspects of PD pathophysiology[63]. Another area of interest is the combination of bromocriptine with neuroprotective agents. Given bromocriptine's potential antioxidant and anti-inflammatory properties, pairing it with other neuroprotective drugs could enhance its ability to slow disease progression. Such combination therapies could target different mechanisms of neuronal degeneration, offering a multifaceted approach to PD treatment[64].

Future Research Needs

Gaps in Current Understanding

Despite the advancements in bromocriptine derivatives, several gaps in our understanding remain[2,5]. One significant gap is the long-term impact of bromocriptine on disease progression. While bromocriptine has shown neuroprotective potential in preclinical studies, more extensive clinical trials are needed to confirm these effects and determine the long-term benefits for PD patients[65]. Another area requiring further investigation is the precise

mechanisms through which bromocriptine exerts its neuroprotective effects. Understanding the molecular pathways involved in its antioxidant and anti-inflammatory actions could help optimize its use and identify biomarkers for predicting patient response[66]. The variability in patient response to bromocriptine also highlights the need for personalized medicine approaches. Factors such as genetic variations, disease stage, and the presence of comorbidities can influence treatment outcomes[23]. Future research should focus on identifying patient subgroups that are most likely to benefit from bromocriptine therapy and developing individualized treatment plans[67].

Potential Areas for Future Investigation

Several promising areas for future investigation could enhance the therapeutic potential of bromocriptine and its derivatives in PD.

1. Enhanced Delivery Systems:

Developing more advanced drug delivery systems, such as nanotechnology-based formulations, could improve the bioavailability and targeted delivery of bromocriptine[2]. These systems could potentially reduce side effects and enhance the drug's efficacy by ensuring it reaches the intended sites of action more effectively[68].

2. Combination with Disease-Modifying Therapies:

Combining bromocriptine with disease-modifying therapies, such as gene therapy or stem cell therapy, could provide synergistic effects. These combinations might enhance the overall therapeutic outcomes by not only alleviating symptoms but also addressing the underlying causes of PD[69].

3. Investigating Non-Motor Symptoms:

While bromocriptine's effects on motor symptoms are well-documented, its impact on non-motor symptoms, such as cognitive impairment, sleep disturbances, and autonomic dysfunction, requires further exploration. Understanding how bromocriptine affects these symptoms could lead to more comprehensive treatment strategies for PD patients[19,7].

4. Neuroprotective Mechanisms:

Elucidating the neuroprotective mechanisms of bromocriptine could open new avenues for therapy. Research into how bromocriptine modulates oxidative stress, neuroinflammation, and mitochondrial function could lead to the development of more potent neuroprotective agents[70].

5. Long-Term Safety and Efficacy:

Long-term studies are essential to evaluate the safety and efficacy of new bromocriptine formulations and delivery methods. These studies should focus on understanding the chronic effects of bromocriptine, particularly regarding its potential to cause fibrosis and other long-term side effects[12,9].

6. Biomarkers for Response Prediction:

Identifying biomarkers that predict response to bromocriptine treatment could facilitate personalized medicine approaches. Such biomarkers could help determine which patients are most likely to benefit from bromocriptine therapy and allow for more tailored treatment plans[3,9]. While significant progress has been made in the development and understanding of bromocriptine derivatives, ongoing research is essential to fully realize their potential in PD treatment[10]. Advances in delivery methods, combination therapies, and personalized medicine approaches will likely play crucial roles in enhancing the efficacy and safety of bromocriptine for PD patients[71].

7. Conclusion

Bromocriptine derivatives are integral to treating Parkinson's Disease (PD), primarily by acting as dopamine agonists that bind to D2 receptors in the brain. This action helps compensate for reduced dopamine levels, alleviating motor symptoms like bradykinesia, rigidity, and tremors. Additionally, bromocriptine modulates dopaminergic pathways, enhancing dopamine synthesis and release in the nigrostriatal pathway, thereby improving motor control and reducing motor fluctuations associated with PD treatment. Beyond symptom management, bromocriptine exhibits neuroprotective effects by reducing oxidative stress and inhibiting neuroinflammation. These properties suggest potential benefits in slowing disease progression, making bromocriptine a versatile treatment option throughout the course of PD. Clinical studies support its efficacy in both early and advanced stages of the disease, either as monotherapy or in combination with other medications like levodopa. This versatility helps manage motor complications such as dyskinesias and fluctuations in motor response to levodopa. Looking forward, bromocriptine derivatives are expected to play a crucial role in future PD treatments. Advances in formulations and delivery methods, such as extended-release formulations and transdermal patches, aim to improve treatment adherence and minimize side effects by providing more consistent drug levels. Additionally, exploring combination therapies with other dopaminergic or neuroprotective agents may enhance overall treatment efficacy while reducing adverse effects. Ongoing research remains critical to fully understanding the long-term safety and efficacy of bromocriptine derivatives. Further studies are needed to elucidate their neuroprotective mechanisms and explore potential biomarkers for predicting treatment response. Personalized medicine approaches could optimize PD treatment by tailoring therapies to individual patient characteristics, thereby improving outcomes and quality of life.

8. References

1. Colao, "Pituitary tumours: the prolactinoma," *Best Pract Res Clin Endocrinol Metab.*, vol. 23, no. 5, pp. 575-596, Oct. 2009.
2. S. Petersenn et al., "Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement," *Nat Rev Endocrinol.*, vol. 19, no. 12, pp. 722-740, Dec. 2023.
3. M. O. Thorner et al., "Bromocriptine treatment of acromegaly," *Br Med J.*, vol. 1, no. 5953, pp. 299-303, Feb. 1975.
4. J. Cassar, K. Mashiter, and G. F. Joplin, "Bromocriptine treatment of acromegaly," *Metabolism*, vol. 26, no. 5, pp. 539-546, May 1977.
5. J. Jankovic, "Parkinson's disease: clinical features and diagnosis," *J Neurol Neurosurg Psychiatry*, vol. 79, no. 4, pp. 368-376, Apr. 2008.
6. N. Lieberman and M. Goldstein, "Bromocriptine in Parkinson disease," *Pharmacol Rev.*, vol. 37, no. 2, pp. 217-227, Jun. 1985.
7. R. L. Stowe et al., "Dopamine agonist therapy in early Parkinson's disease," *Cochrane Database Syst Rev.*, no. 2, CD006564, Apr. 2008.
8. D. J. Brooks, "Dopamine agonists: their role in the treatment of Parkinson's disease," *J Neurol Neurosurg Psychiatry*, vol. 68, no. 6, pp. 685-689, Jun. 2000.

9. K. E. Kryczka, M. Demkow, and Z. Dzielińska, "Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found," *Biomolecules*, vol. 14, no. 1, Jan. 2024.
10. Kumar et al., "Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis," *Curr Probl Cardiol.*, vol. 48, no. 2, 101461, Feb. 2023.
11. Velosa et al., "Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach," *BMJ Case Rep.*, vol. 12, no. 6, Jun. 2019.
12. D. J. Pileggi and A. M. Cook, "Neuroleptic Malignant Syndrome," *Ann Pharmacother.*, vol. 50, no. 11, pp. 973-981, Nov. 2016.
13. National Institute of Diabetes and Digestive and Kidney Diseases, "LiverTox: Clinical and Research Information on Drug-Induced Liver Injury," Bethesda (MD), Jul. 20, 2017.
14. S. Hisahara and S. Shimohama, "Dopamine receptors and Parkinson's disease," *Int J Med Chem.*, vol. 2011, article ID 403039, 2011.
15. H. M. Johnson et al., "ABM Clinical Protocol #32: Management of Hyperlactation," *Breastfeed Med.*, vol. 15, no. 3, pp. 129-134, Mar. 2020.
16. M. D. Latt et al., "Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease," *Drugs Aging*, vol. 36, no. 3, pp. 189-202, Mar. 2019.
17. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (*Echinochloa esculenta*) starch," *ACS Omega*, vol. 8, no. 33, pp. 30294–305, 2023.
18. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," *Pharmaceutics*, vol. 15, no. 8, p. 2066, 2023.
19. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," *Pharma Science Monitor*, vol. 9, no. 2, 2018.
20. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," *Int J Pharm Investig*, vol. 11, no. 1, pp. 69–75, 2021.
21. Colao et al., "Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women," *Nat Clin Pract Endocrinol Metab.*, vol. 2, no. 4, pp. 200-210, Apr. 2006.
22. Weil, "The safety of bromocriptine in long-term use: a review of the literature," *Curr Med Res Opin.*, vol. 10, no. 1, pp. 25-51, Jan. 1986.
23. Hamidianjahromi and N. A. Tritos, "Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy," *Rev Endocr Metab Disord.*, vol. 23, no. 5, pp. 1089-1099, Oct. 2022.
24. P. Krupp and C. Monka, "Bromocriptine in pregnancy: safety aspects," *Klin Wochenschr.*, vol. 65, no. 17, pp. 823-827, Sep. 1987.
25. S. H. Vermund, R. G. Goldstein, A. A. Romano, and S. J. Atwood, "Accidental bromocriptine ingestion in childhood," *J Pediatr.*, vol. 105, no. 5, pp. 838-840, Nov. 1984.
26. L. Lemieux-Charles and W. L. McGuire, "What do we know about health care team effectiveness? A review of the literature," *Med Care Res Rev.*, vol. 63, no. 3, pp. 263-300, Jun. 2006.

27. N. Green and C. D. Johnson, "Interprofessional collaboration in research, education, and clinical practice: working together for a better future," *J Chiropr Educ.*, vol. 29, no. 1, pp. 1-10, Mar. 2015.
28. R. Bridges, R. A. Davidson, P. S. Odegard, I. V. Maki, and J. Tomkowiak, "Interprofessional collaboration: three best practice models of interprofessional education," *Med Educ Online*, vol. 16, Apr. 2011.
29. Dharmendra Bhati et al., "FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.749>.
30. K. J. Mangala et al., "NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.553>.
31. Rohit Kumar Trivedi et al., "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.521>.
32. H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.457>.
33. M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: <https://doi.org/10.51470/bca.2023.23.s1.1655>.
34. S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: <https://doi.org/10.51470/bca.2023.23.s1.1415>.
35. M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," *NeuroQuantology*, vol. 20, no. 11, pp. 1258, 2022.
36. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in *2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI)*. IEEE, 2022.
37. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," *International Journal of Pharmaceutical Sciences and Research*, vol. 11, no. 5, pp. 2193–2198, 2020.
38. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," *GSC biol pharm sci*, vol. 19, no. 3, pp. 148–155, 2022.
39. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., *Encyclopedia of green materials*. Singapore: Springer Nature Singapore, 2022.
40. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," *Am J PharmTech Res*, vol. 9, no. 3, pp. 321–331, 2019.

41. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in *The Flavonoids*, 2024, pp. 131-152.
42. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," *The Chinese Journal of Artificial Intelligence*, 2023.
43. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in *Blockchain for Healthcare Systems*, 2021, pp. 97–113.
44. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," *World J. Pharm. Pharm. Sci*, vol. 7, no. 9, pp. 271-287, 2018.
45. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," *Res J Pharm Technol*, pp. 5078–5083, 2022.
46. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," *J Pharm Res Int*, pp. 70–78, 2021.
47. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," *Phytomed Plus*, vol. 3, no. 2, p. 100445, 2023.
48. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," *J Chem Pharm Sci*, vol. 12, no. 03, pp. 71–78, 2019.
49. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," *Nat Prod J*, 2022.
50. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," *ACS Omega*, vol. 7, no. 40, pp. 35506–35514, 2022.
51. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," *ACS Omega*, vol. 8, no. 13, pp. 11750–11767, 2023.
52. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," *J Pharm Res Int*, pp. 54–63, 2021.
53. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," *J Pharm Res Int*, pp. 21–29, 2021.
54. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," *Journal of Pharmaceutical Negative Results*, pp. 1811-1820, 2022.
55. K. K. Sahu et al., "Utility of nanomaterials in wound management," in *Nanotechnological Aspects for Next-Generation Wound Management*, 2024, pp. 101–130.
56. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," *J Infect Public Health*, vol. 15, no. 5, pp. 566–572, 2022.
57. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," *J Pharm Res Int*, pp. 5–13, 2021.
58. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," *Journal of Pharmaceutical Research International*, vol. 32, no. 36, pp. 82-88, 2022.
59. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," *WJPMR*, vol. 8, no. 4, pp. 216–225, 2022.

60. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in *Advances in Flavonoids for Human Health and Prevention of Diseases*, 2024, pp. 23-46.
61. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in *Blockchain for Healthcare Systems*, 2021, pp. 61–79.
62. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," *Journal of Pharmaceutical Negative Results*, pp. 1463-1469, 2022.
63. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in *2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART)*, 2023, pp. 556-561.
64. P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (*Echinochloa frumentacea*) Grains Starch," *Stärke/Starch*, May 2024, doi: <https://doi.org/10.1002/star.202300285>.
65. V. Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," *Journal of bioactive and compatible polymers*, May 2024, doi: <https://doi.org/10.1177/08839115241249143>.
66. P. Fitzgerald and T. G. Dinan, "Prolactin and dopamine: what is the connection? A review article," *J Psychopharmacol.*, vol. 22, no. 2 Suppl, pp. 12-19, Mar. 2008.
67. Shivaprasad and S. Kalra, "Bromocriptine in type 2 diabetes mellitus," *Indian J Endocrinol Metab.*, vol. 15, Suppl 1, pp. S17-S24, Jul. 2011.
68. M. A. Via et al., "Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes," *Diabetes Metab Syndr Obes.*, vol. 3, pp. 43-48, Mar. 2010.
69. R. I. Holt, A. H. Barnett, and C. J. Bailey, "Bromocriptine: old drug, new formulation and new indication," *Diabetes Obes Metab.*, vol. 12, no. 12, pp. 1048-1057, Dec. 2010.
70. J. Verhelst and R. Abs, "Hyperprolactinemia: pathophysiology and management," *Treat Endocrinol.*, vol. 2, no. 1, pp. 23-32, Jan. 2003.
71. National Institute of Child Health and Human Development, "Drugs and Lactation Database (LactMed®)," Bethesda (MD), Aug. 15, 2023.